GET THE APP

Women cancer risk and Polycystic ovary syndrome (PCOS) | 19971
Endocrinology & Metabolic Syndrome

Endocrinology & Metabolic Syndrome
Open Access

ISSN: 2161-1017

Women cancer risk and Polycystic ovary syndrome (PCOS)


4th World Congress on Polycystic Ovarian Syndrome

October 26-27, 2018 | Boston, USA

Dalida Omar Badla

Damascus University, Syria

Keynote: Endocrinol Metab Syndr

Abstract :

Polycystic ovary syndrome (PCOS): It is a complex endocrine disorder characterized by oligomenorrhea, hyperandrogenism, and polycystic ovariesshape by ultrasound. It has an estimated prevalence of 4�??21% in reproductive-aged women depending on the diagnostic criteria and population examine. PCOS is associated with metabolic abnormalities including dyslipidemia, insulin resistance, and type II diabetes and is also one of the most common causes of reduced fertility. The altered metabolic and hormonal environment among women with PCOS may increase their risk of some types of cancer.like: Endometrial cancer which explained by the absence of ovulation and producing estrogen, but not progesterone, which causes the endometrium (the lining of the uterus) to grow too much and undergo atypical cell changes. This is a pre-cancerous condition called endometrial hyperplasia. If the thickened endometrium is not treated, over a long period of time it can develop into endometrial cancer, and Ovarian Cancer: AS PCOS increased androgen exposure presence of androgen receptors on normal ovarian cells as well as benign and borderline tumors, and a doubling of androgen levels during pregnancy is associated with a 40�??50% increased risk of borderline serous and invasive. Breast Cancer: Characteristics and consequences of PCOS have been previously associated with both increased and decreased risk of breast cancer. increased levels of insulin in the blood can increase the risk of formation of breast cancer cells. and Other kinds of cancers might be linked to Also PCOS medications that may influence cancer risk such as Oral contraceptives, Metformin, Ovulation-induction therapies.

Biography :

Dalida Omar Badla has completed MBBS from the faculty of medicine of Damascus University-Syria in 1990 and had the certificate of specialist registration in ob&gyn from Ministry of Health OF Syria in 1994 then Master degree (MD)from University Hospital of Aleppo-Syria in 1995.Syrian Board in 2015.Diploma in Minimal Access Surgery D.MAS from World Association of Laparoscopic Surgeons in 2017. Fellowship in Assisted Reproductive Technology from International Association of Assisted Reproductive Technology at WLH, NCR DELHI in 2017. She is a specialist of Obstetric and Gynaecology at Danat Al Emarat hospital for Women and Child Health in Abu Dhabi, UAE

E-mail: dalida-ma@hotmail.com

 

Top